Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation.

Hideki Ijichi; Tomoharu Yoshizumi; Toru Ikegami; Yuji Soejima; Tetsuo Ikeda; Hirofumi Kawanaka; Hideaki Uchiyama; Yo Ichi Yamashita; Masaru Morita; Eiji Oki; Koshi Mimori; Keishi Sugimachi; Hiroshi Saeki; Masayuki Watanabe; Ken Shirabe; Yoshihiko Maehara

Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation.

Hideki Ijichi, Tomoharu Yoshizumi, Toru Ikegami, Yuji Soejima, Tetsuo Ikeda, Hirofumi Kawanaka, Hideaki Uchiyama, Yo Ichi Yamashita, Masaru Morita, Eiji Oki, Koshi Mimori, Keishi Sugimachi, Hiroshi Saeki, Masayuki Watanabe, Ken Shirabe, Yoshihiko Maehara

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Hepatitis B virus (HBV) recurrence after liver transplantation for HBV-associated liver diseases results in decreased patient and graft survival. Herein we have reported two cases of HBV recurrence following relapse of hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT). Both cases had LDLT for end-stage liver disease secondary to HBV infection with nodules of HCC exceeding the Milan criteria. HBV prophylaxis using hepatitis B immunoglobulin with nucleos (t) ide analogues were given and HBV DNA levels were consistently undetectable after LDLT. HCC recurred at 5 months and 13 months posttransplant respectively, and chemotherapy and radiation therapy were performed. HBV recurrence occurred during the treatment of HCC. HBV DNA levels increased despite the treatment with anti-HBV agents after HBV recurrence. In hepatitis B surface antigen positive recipients, HBV prophylaxis should be intensified during the treatment of recurrent HCC.

Original language	English
Pages (from-to)	376-382
Number of pages	7
Journal	Unknown Journal
Volume	104
Issue number	10
Publication status	Published - Oct 2013

All Science Journal Classification (ASJC) codes

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{e94a1bc254554a498e55d9c0372f553f,

title = "Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation.",

abstract = "Hepatitis B virus (HBV) recurrence after liver transplantation for HBV-associated liver diseases results in decreased patient and graft survival. Herein we have reported two cases of HBV recurrence following relapse of hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT). Both cases had LDLT for end-stage liver disease secondary to HBV infection with nodules of HCC exceeding the Milan criteria. HBV prophylaxis using hepatitis B immunoglobulin with nucleos (t) ide analogues were given and HBV DNA levels were consistently undetectable after LDLT. HCC recurred at 5 months and 13 months posttransplant respectively, and chemotherapy and radiation therapy were performed. HBV recurrence occurred during the treatment of HCC. HBV DNA levels increased despite the treatment with anti-HBV agents after HBV recurrence. In hepatitis B surface antigen positive recipients, HBV prophylaxis should be intensified during the treatment of recurrent HCC.",

author = "Hideki Ijichi and Tomoharu Yoshizumi and Toru Ikegami and Yuji Soejima and Tetsuo Ikeda and Hirofumi Kawanaka and Hideaki Uchiyama and Yamashita, {Yo Ichi} and Masaru Morita and Eiji Oki and Koshi Mimori and Keishi Sugimachi and Hiroshi Saeki and Masayuki Watanabe and Ken Shirabe and Yoshihiko Maehara",

year = "2013",

month = oct,

language = "English",

volume = "104",

pages = "376--382",

journal = "Unknown Journal",

issn = "1040-6182",

publisher = "Elsevier Limited",

number = "10",

}

TY - JOUR

T1 - Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation.

AU - Ijichi, Hideki

AU - Yoshizumi, Tomoharu

AU - Ikegami, Toru

AU - Soejima, Yuji

AU - Ikeda, Tetsuo

AU - Kawanaka, Hirofumi

AU - Uchiyama, Hideaki

AU - Yamashita, Yo Ichi

AU - Morita, Masaru

AU - Oki, Eiji

AU - Mimori, Koshi

AU - Sugimachi, Keishi

AU - Saeki, Hiroshi

AU - Watanabe, Masayuki

AU - Shirabe, Ken

AU - Maehara, Yoshihiko

PY - 2013/10

Y1 - 2013/10

N2 - Hepatitis B virus (HBV) recurrence after liver transplantation for HBV-associated liver diseases results in decreased patient and graft survival. Herein we have reported two cases of HBV recurrence following relapse of hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT). Both cases had LDLT for end-stage liver disease secondary to HBV infection with nodules of HCC exceeding the Milan criteria. HBV prophylaxis using hepatitis B immunoglobulin with nucleos (t) ide analogues were given and HBV DNA levels were consistently undetectable after LDLT. HCC recurred at 5 months and 13 months posttransplant respectively, and chemotherapy and radiation therapy were performed. HBV recurrence occurred during the treatment of HCC. HBV DNA levels increased despite the treatment with anti-HBV agents after HBV recurrence. In hepatitis B surface antigen positive recipients, HBV prophylaxis should be intensified during the treatment of recurrent HCC.

AB - Hepatitis B virus (HBV) recurrence after liver transplantation for HBV-associated liver diseases results in decreased patient and graft survival. Herein we have reported two cases of HBV recurrence following relapse of hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT). Both cases had LDLT for end-stage liver disease secondary to HBV infection with nodules of HCC exceeding the Milan criteria. HBV prophylaxis using hepatitis B immunoglobulin with nucleos (t) ide analogues were given and HBV DNA levels were consistently undetectable after LDLT. HCC recurred at 5 months and 13 months posttransplant respectively, and chemotherapy and radiation therapy were performed. HBV recurrence occurred during the treatment of HCC. HBV DNA levels increased despite the treatment with anti-HBV agents after HBV recurrence. In hepatitis B surface antigen positive recipients, HBV prophylaxis should be intensified during the treatment of recurrent HCC.

UR - http://www.scopus.com/inward/record.url?scp=84897577066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897577066&partnerID=8YFLogxK

M3 - Article

C2 - 24511669

AN - SCOPUS:84897577066

SN - 1040-6182

VL - 104

SP - 376

EP - 382

JO - Unknown Journal

JF - Unknown Journal

IS - 10

ER -

Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation.

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this